SERVICE DETAIL
IN-SILICO CLINICAL TRIALS &
REAL-WORLD EVIDENCE (RWE)
The Algorithmic Mandate
The traditional clinical trial paradigm is unsustainably slow, financially prohibitive, and frequently lacks multi-ancestry representation. Furthermore, rare cancers often lack enough patients to form traditional physical control groups.
KCCIRC’s In-Silico Trials division leverages Casual AI and massive data lakes to revolutionize the evidence generation paradigm and accelerate regulatory approvals.
Core Capabilities & Methodologies
Synthetic Control Arms (SCA)
We bypass the ethical and logistical bottlenecks of placebo groups in precision oncology.
Regulatory-Grade Cohort Generation:
Utilizing probabilistic graphical models and vast repositories of existing clinical evidence, we construct high-fidelity Synthetic Control Arms. This allows us to dramatically accelerate Phase II/III trial timelines for rare solid cancers and uncommon blood tumours.
Algorithmic Bias Mitigation:
We rigorously audit all our AI architectures for algorithmic bias. By carefully balancing our Synthetic Control Arms, we ensure equitable, multi-ancestry representation that is often missing from traditional physical trials.
Real-World Evidence (RWE) & Causal Inference
We continuously mine longitudinal Real-World Data (RWD) from global electronic health records, insurance claims, and genomic registries.
Post-Market Surveillance:
We apply advanced causal inference frameworks to evaluate the long-term, post-market efficacy of novel therapeutics in diverse, non-trial patient populations.
Clinical NLP for Adverse Reactions:
Utilizing our Agentic BioNLM infrastructure, we deploy Natural Language Processing to rapidly track subtle, emergent adverse drug reactions hidden within unstructured clinical notes.
CLINICAL IMPACT
Our In-Silico Trials infrastructure saves millions of dollars and years of development time for biotech and pharmaceutical innovators.